Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Gerontology
Published in: Advances in Gerontology 3/2020

01-07-2020 | Breast Cancer

The Use of Geroprotective Agents (mTOR Inhibitors) in the Treatment of Cancer Patients

Author: M. N. Yurova

Published in: Advances in Gerontology | Issue 3/2020

Login to get access

Abstract

The review discusses experimental and clinical data from recent decades on the use of geroprotective agents of the mTOR inhibitor group for the main and accompanying treatment of cancer patients. The mTOR protein kinase is an interesting therapeutic target for the treatment of multiple cancers with both mTOR inhibitors themselves (rapamycin and its derivatives) and in combination with inhibitors of other pathways (e.g., metformin). mTOR inhibitors, which are not classical cytostatic agents and do not possess carcinogenic activity, show great promise as independent antitumor agents and in combination with conventional chemotherapy.
Literature
1.
Andre, F., O’Regan, R., Ozguroglu, M., et al., Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomized, double-blind, placebocontrolled phase 3 trial, Lancet Oncol., 2014, vol. 15, pp. 580–591.PubMed
2.
Anisimov, V.N., Metformin for prevention and treatment of colon cancer: a reappraisal of experimental and clinical data, Curr. Drug Targets, 2016, vol. 17, no. 4, pp. 439–446.PubMed
3.
Anisimov, V.N., Berstein, L.M., Egormin, P.A., et al., Metformin slows down aging and extends life span of female SHR mice, Cell Cycle, 2008, vol. 7, no. 17, pp. 2769–2773.PubMed
4.
Anisimov, V.N., Egormin, P.A., Bershtein, L.M., et al., Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice, Bull. Exp. Biol. Med., 2005, vol. 139, no. 6, pp. 721–723.PubMed
5.
Anisimov, V.N., Zabezhinski, M.A., Popovich, I.G., et al., Rapamycin extends maximal lifespan in cancer-prone mice, Am. J. Pathol., 2010, vol. 176, no. 5, pp. 2092–2097.PubMedPubMedCentral
6.
Anisimov, V.N., Zabezhinski, M.A., Popovich, I.G., et al., Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice, Cell Cycle, 2011, vol. 10, no. 24, pp. 4230–4236.PubMed
7.
Apontes, P., Leontieva, O.V., Demidenko, Z.N., et al., Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture, Oncotarget, 2011, vol. 2, pp. 222–233.PubMedPubMedCentral
8.
Arriola Apelo, S.I. and Lamming, D.W., Rapamycin: an inhibiTOR of aging emerges from the soil of Easter Island, J. Gerontol., A, 2016, vol. 71, no. 7, pp. 841–849.
9.
Bent, E.H., Gilbert, L.A., and Hemann, M.T., A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses, Genes Dev., 2016, vol. 30, no. 16, pp. 1811–1821.PubMedPubMedCentral
10.
Berstein, L.M., Vasilyev, D.A., Iyevleva, A.G., et al., Potential and real ‘antineoplastic’ and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females, Future Oncol., 2015, vol. 11, no. 5, pp. 759–770.PubMed
11.
Blagosklonny, M.V., Answering the ultimate question “What is the proximal cause of aging?,” Aging (Albany, NY), 2012, vol. 4, no. 12, pp. 861–877.
12.
Blagosklonny, M.V., Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging, Aging (Albany, NY), 2012, vol. 4, no. 3, pp. 159–165.
13.
Blagosklonny, M.V. and Darzynkiewicz, Z., Cyclotherapy: protection of normal cells and unshielding of cancer cells, Cell Cycle, 2002, vol. 1, no. 6, pp. 375–382.PubMed
14.
Campone, M., Levy, V., Bourbouloux, E., et al., Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumors, Br. J. Cancer, 2009, vol. 100, no. 2, pp. 315–321.PubMedPubMedCentral
15.
Chatterjee, A., Mukhopadhyay, S., Tung, K., et al., Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways, Cancer Lett., 2015, vol. 360, no. 2, pp. 134–140.PubMedPubMedCentral
16.
Cifarelli, V., Lashinger, L.M., Devlin, K.L., et al., Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms, Diabetes, 2015, vol. 64, no. 5, pp. 1632–1642.PubMedPubMedCentral
17.
Currie, C.J., Poole, C.D., and Gale, E.A., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, 2009, vol. 52, no. 9, pp. 1766–1777.PubMed
18.
Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., et al., Metformin and reduced risk of cancer in diabetic patients, Br. Med. J., 2005, vol. 330, no. 7503, pp. 1304–1305.
19.
Fiebrich, H.B., Siemerink, E.J., Brouwers, A.H., et al., Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues, Oncologist, 2011, vol. 16, pp. 783–787.PubMedPubMedCentral
20.
Granville, C.A., Warfel, N., Tsurutani, J., et al., Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity and phenotypic progression of tobacco carcinogen-induced murine lung tumors, Clin. Cancer Res., 2007, vol. 13, no. 7, pp. 2281–2289.PubMed
21.
Grozinsky-Glasberg, S. and Shimon, I., The potential role of mTOR inhibitors in the treatment of endocrine tumors, J. Endocrinol. Invest., 2010, vol. 33, no. 4, pp. 276–281.PubMed
22.
Guertin, D.A. and Sabatini, D.M., Defining the role of mTOR in cancer, Cancer Cell, 2007, vol. 12, pp. 9–22.PubMed
23.
Hanly, E.K., Bednarczyk, R.B., Tuli, N.Y., et al., mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib, Oncotarget, 2015, vol. 6, no. 37, pp. 39 702–39 713.
24.
Hare, S.H. and Harvey, A.J., mTOR function and therapeutic targeting in breast cancer, Am. J. Cancer Res., 2017, vol. 7, no. 3, pp. 383–404.PubMedPubMedCentral
25.
Harrison, D.E., Strong, R., Sharp, Z.D., et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice, Nature, 2009, vol. 460, no. 7253, pp. 392–395.PubMedPubMedCentral
26.
Hau, A.M., Nakasaki, M., Nakashima, K., et al., Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition, Urol. Oncol., 2017, vol. 17, pp. 30 134–30 135.
27.
Hay, N. and Sonenberg, N., Upstream and downstream of mTOR, Genes Dev., 2004, vol. 18, no. 16, pp. 1926–1945.PubMed
28.
Hobday, T.J., Qin, R., Reidy-Lagunes, D., et al., Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors, J. Clin. Oncol., 2015, vol. 33, pp. 1551–1556.PubMed
29.
Hoda, M.A., Mohamed, A., Ghanim, B., et al., Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy, J. Thorac. Oncol., 2011, vol. 6, no. 5, pp. 852–863.PubMed
30.
Hurvitz, S.A., Dalenc, F., Campone, M., et al., A Phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overex-pressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy, Breast Cancer Res. Treat., 2013, vol. 141, pp. 437–446.PubMedPubMedCentral
31.
Iorio, A.L., Da Ros, M., Pisano, C., et al., Combined treatment with doxorubicin and rapamycin is effective against in vitro and in vivo models of human glioblastoma, J. Clin. Med., 2019, vol. 8, no. 3, p. 331.PubMedCentral
32.
Johnston, O., Rose, C.L., Webster, A.C., and Gill, J.S., Sirolimus is associated with new-onset diabetes in kidney transplant recipients, J. Am. Soc. Nephrol., 2008, vol. 19, pp. 1411–1418.PubMedPubMedCentral
33.
Kangwan, N., Park, J.M., Kim, E.H., and Hahm, K.B., Chemoquiescence for ideal cancer treatment and prevention: where are we now?, J. Cancer Prev., 2014, vol. 19, no. 2, pp. 89–96.PubMedPubMedCentral
34.
Kranz, D. and Dobbelstein, M., A killer promoting survival-p53 as a selective means to avoid side effects of chemotherapy, Cell Cycle, 2012, vol. 11, no. 11, pp. 2053–2054.PubMed
35.
Lee, J.S., Vo, T.T., and Fruman, D.A., Targeting mTOR for the treatment of B cell malignancies, Br. J. Clin. Pharmacol., 2016, vol. 82, no. 5, pp. 1213–1228.PubMedPubMedCentral
36.
Leontieva, O.V., Paszkiewicz, G.M., and Blagosklonny, M.V., Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet, Aging Cell, 2014, vol. 13, no. 4, pp. 616–622.PubMedPubMedCentral
37.
Ling, S., Feng, T., Ke, Q., et al., Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines, Oncol. Rep., 2014, vol. 31, no. 6, pp. 2611–2618.PubMed
38.
Liu, B., Fan, Z., Edgerton, S.M., et al., Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interaction, Cell Cycle, 2011, vol. 10, no. 17, pp. 2959–2966.PubMed
39.
Mabuchi, S., Hisamatsu, T., and Kimura, T., Targeting mTOR signaling pathway in ovarian cancer, Curr. Med. Chem., 2011, vol. 18, no. 19, pp. 2960–2968.PubMed
40.
Mondesire, W.H., Jian, W., Zhang, H., et al., Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells, Clin. Cancer Res., 2004, vol. 10, no. 20, pp. 7031–7042.PubMed
41.
Motzer, R.J., Escudier, B., Oudard, S., et al., Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo-controlled phase III trial, Lancet, 2008, vol. 372, pp. 449–456.PubMed
42.
Onoda, N., Nakamura, M., Aomatsu, N., et al., Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation, Mol. Clin. Oncol., 2015, vol. 3, no. 3, pp. 522–526.PubMedPubMedCentral
43.
Piguet, A.C., Semela, D., Keogh, A., et al., Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma, J. Hepatol., 2008, vol. 49, pp. 78–87.PubMed
44.
Popovich, I.G., Anisimov, V.N., Zabezhinski, M.A., et al., Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin, Cancer Biol. Ther., 2014, vol. 15, no. 5, pp. 586–592.PubMedPubMedCentral
45.
Rao, B., Lain, S., and Thompson, A.M., p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy, Br. J. Cancer, 2013, vol. 109, pp. 2954–2958.PubMedPubMedCentral
46.
Sabatini, D.M., mTOR: from growth signal integration to cancer, diabetes and ageing, Nat. Rev. Mol. Cell Biol., 2011, vol. 12, pp. 21–35.PubMed
47.
Saha, A., Blando, J., Tremmel, L., and DiGiovanni, J., Effect of metformin, rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice, Cancer Prev. Res., 2015, vol. 8, no. 7, pp. 597–606.
48.
Shaw, R.J., Lamia, K.A., Vasquez, D., et al., The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin, Science, 2005, vol. 310, no. 5754, pp. 1642–1646.PubMedPubMedCentral
49.
Shen, Ch., Peng, Ch., Shen, B., et al., Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation, Oncotarget, 2016, vol. 7, no. 38, pp. 62 647–62 656.
50.
Shimazu, K., Tada, Y., Morinaga, T., et al., Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways, BMC Cancer, 2017, vol. 17, no. 1, p. 309.PubMedPubMedCentral
51.
Song, Y., Xue, H., Liu, T.T., et al., Rapamycin plays a neuroprotective effect after spinal cord injury via anti-inflammatory effects, J. Biochem. Mol. Toxicol., 2015, vol. 29, no. 1, pp. 29–34.PubMed
52.
Stanfel, M.N., Shamieh, L.S., Kaeberlein, M., and Kennedy, B.K., The TOR pathway comes of age, Biochim. Biophys. Acta, Gen. Subj., 2009, vol. 1790, pp. 1067–1074.
53.
Trelinska, J., Dachowska, I., Kotulska, K., et al., Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening, Anticancer Drugs, 2015, vol. 26, pp. 437–442.PubMed
54.
van Leeuwen, I.M., Cyclotherapy: opening a therapeutic window in cancer treatment, Oncotarget, 2012, vol. 3, pp. 596–600.PubMedPubMedCentral
55.
van Leeuwen, I.M. and Lain, S., Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs, Oncotarget, 2011, vol. 2, no. 4, pp. 274–276.PubMedPubMedCentral
56.
van Leeuwen, I.M., Rao, B., Sachweh, M.C., and Laín, S., An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells, Cell Cycle, 2012, vol. 11, no. 9, pp. 1851–1861.PubMedPubMedCentral
57.
58.
Vignot, S., Faivre, S., Aguirre, D., and Raymond, E., mTOR-targeted therapy of cancer with rapamycin derivatives, Ann. Oncol., 2005, vol. 16, no. 4, pp. 525–537.PubMed
59.
Wang, D. and Wu, X., In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin, Oncol. Lett., 2015, vol. 10, no. 2, pp. 975–981.PubMedPubMedCentral
60.
Wang, X.W. and Zhang, Y.J., Targeting mTOR network in colorectal cancer therapy, World J. Gastroenterol., 2014, vol. 20, no. 15, pp. 4178–4188.PubMedPubMedCentral
61.
Wang, Y., Wei, J., Li, L., et al., Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells, Oncol. Res., 2014, vol. 22, no. 4, pp. 193–201.PubMed
62.
Wilkinson, J.E., Burmeister, L., Brooks, S.V., et al., Rapamycin slows aging in mice, Aging Cell, 2012, vol. 11, no. 4, pp. 675–682.PubMed
63.
Xiong, Y., Zhao, Y., Miao, L., et al., Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer, J. Control Release, 2016, vol. 244, pp. 63–73.PubMedPubMedCentral
64.
Yang, J., Samsel, P.A., Narov, K., et al., Combination of everolimus with sorafenib for solid renal tumors in Tsc2 +/– mice is duperior to everolimus alone, Neoplasia, 2017, vol. 19, no. 2, pp. 112–120.PubMedPubMedCentral
65.
Yu, G., Fang, W., Xia, T., et al., Metformin potentiates rapamycin and cisplatin in gastric cancer in mice, Oncotarget, 2015, vol. 6, no. 14, pp. 12 748–12 762.
66.
Zou, H., Li, L., Garcia Carcedo, I., et al., Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis, Int. J. Nanomed., 2016, vol. 11, pp. 1947–1958.
Metadata
Title
The Use of Geroprotective Agents (mTOR Inhibitors) in the Treatment of Cancer Patients
Author
M. N. Yurova
Publication date
01-07-2020
Publisher
Pleiades Publishing
Published in
Advances in Gerontology / Issue 3/2020
Print ISSN: 2079-0570
Electronic ISSN: 2079-0589
DOI
https://doi.org/10.1134/S2079057020030170

Other articles of this Issue 3/2020

Advances in Gerontology 3/2020 Go to the issue

OriginalPaper

Diagnostic Criteria and Prevalence of Sarcopenia in the Elderly

OriginalPaper

U-133, a Chaperone Inducer, Eliminates Sleep Disturbances in a Model of the Preclinical Stage of Parkinson’s Disease in Aged Rats

OriginalPaper

Stimulating Effect of the Water-Soluble Fraction from Brown Algae Fucus vesiculosus Extract on Cell Proliferation in the Tissue Culture of Young and Old Rats

OriginalPaper

An Experiment on Age-Related Characteristics of the Reaction of Lung Tissue and Surfactant to Hypobaric Hypoxia and Hyperbaric Hyperoxia

OriginalPaper

Age-Related Physiological and Pathophysiological Features of the Masticatory Apparatus in Adults

OriginalPaper

Hormonal Characteristics of Androgen Status in Males of Different Age Groups
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits